Form 4: Bioadaptives Director Mark P. Frissora Reports Acquisition of Series D Convertible Preferred Stock and Option Grant

Director Mark P. Frissora reports acquiring Series D Convertible Preferred Stock and an option to purchase common stock in Bioadaptives, Inc.

Summary

• Mark P. Frissora, a director of Bioadaptives, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report includes acquisitions of Series D Convertible Preferred Stock on multiple dates: February 15, 2025, March 15, 2025, April 9, 2025 and April 15, 2025.
• Frissora also acquired an option to purchase 500,000 shares of common stock on April 9, 2025, granted in connection with a Preferred D Stock Purchase Agreement.
• The Series D Convertible Preferred Stock is convertible into common stock at a ratio of 100 shares of common stock per share of preferred stock, subject to a 10% beneficial ownership limitation.
• The conversion of preferred stock is restricted for six months after issuance, except in the event of liquidation.
• The Series D Convertible Preferred Stock grants 100 votes per share on matters of the Issuer, without regard to the beneficial ownership limitation.
• Some shares of Series D Convertible Preferred Stock were issued as compensation for board services, based on the closing price of Bioadaptives' common stock on specific dates.
• The option to purchase common stock has an exercise price of $10 and expires on April 9, 2035.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing insider transactions. While the acquisition of shares by a director can be seen as a positive signal, the overall sentiment is neutral as it primarily reflects compliance with reporting requirements.

Positives

• The acquisition of shares by a director could be interpreted as a sign of confidence in the company's future prospects.
• The option grant incentivizes the director to work towards increasing the company's value.

Risks

• The conversion of the Series D Convertible Preferred Stock could dilute existing shareholders' equity.
• The 10% beneficial ownership limitation on conversion could impact the director's ability to fully convert their holdings.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The acquisition of preferred stock and options is a common form of compensation for directors and executives.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, stock options, and restricted stock units.
• The specific terms of the Series D Convertible Preferred Stock, such as the conversion ratio and voting rights, are specific to Bioadaptives and would need to be compared to similar instruments in comparable companies to assess their relative value.
• Comparing the option's exercise price and term to those of options granted to directors at similar companies would provide context.

Stakeholder Impact

• Shareholders may view the director's stock acquisitions as a positive sign, potentially increasing investor confidence.
• The potential dilution from the conversion of preferred stock could be a concern for existing shareholders.

Key Dates

Keywords

Series D Convertible Preferred Stock, Form 4, Beneficial Ownership, Director, Bioadaptives, Option, BDPT